ISU Abxis’ Gaucher disease drug enters Middle East-North African market
ISU Abxis, an affiliate of the ISU Group, is stepping up the launch of its Gaucher disease treatment Abcertin (imiglucerase) in the Middle East and North African (MENA) market. ISU Abxis said Thursday that it has signed an exclusive licensing and supply …